Skip to content
DraconiticResearch
Search Sources API
203,948 studies31 sourcesUpdated 17 min ago

Oncology

5,176 studies502 in 7 days2,477 in 30 days

Filters
Type
Date
Clear

Latest

5,176 studies

  1. 317 Advancing allogeneic CARMAIT cell therapy: isolation, expansion, and engineering for cancer and immune disorders
    Hua Zhang, Meng Huang, Jingyu Li +6
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYFull textOncologyDOAJ
  2. 1132 Spatial mapping and significance of the IL-12 pathway in human colorectal cancer
    Juan Guiza Higuera, Lucy Zheng, Luciene Borges +4
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYFull textOncologyDOAJ
  3. 1116 Mechanisms of tumor-intrinsic immune cloaking in neoantigen-rich cancers
    Arup Chakraborty, Salah Boudjadi, Sandeep Gurram +16
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYFull textOncologyDOAJ
  4. Associations between pretreatment systemic immune-inflammation index and tumor-specific prognosis in breast and gynecological cancers: an updated systematic review, meta-analysis, and certainty-of-evidence assessment
    Junru Tong, Junyou Su, Hongfei Chen +5
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyCrossref
  5. 10-year follow-up of a patient with high-grade serous ovarian carcinoma and concomitant Henoch-Schönlein purpura nephritis, with metachronous liver and brain metastases: a case report
    Di Wang, Lu Wang, Zhifa Zhu +4
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyCrossref
  6. Primary rectal malignant melanoma: a rare case report
    Yang Xiao, MingWang Li, Xia Ye +1
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyCrossref
  7. Association of different traditional Chinese medicine treatment strategies with overall survival in patients with metastatic colorectal cancer: a multicenter real-world cohort study
    Mengmeng Wang, Rui Li, Beibei Wu +3
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyCrossref
  8. A novel RUNX1::ANKLE2 fusion in high-risk MDS with progression to AML: a case report
    Li Liu, Miao Zhao, Yonghong Tan +7
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyCrossref
  9. Integrative bioinformatics and drug response profiling identify MEK/ERK inhibition as a strategy to overcome venetoclax resistance in AML
    Abeer A. Al-Ogailan, Sherin Bakhashab, Abdul Ali Peer-Zada +1
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyCrossref
  10. MiRNA-1915-3p dysregulation characterizes aggressive CRBP1-expressing lung adenocarcinoma cells in vitro and in patient-derived tissues
    Amedeo Ferlosio, Federica Centofanti, Elena Doldo +5
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefDOAJ
  11. Statin use and colorectal cancer prognosis: an updated systematic review and meta-analysis
    Tao Jiang, Jiaxin Wu, Lichao Fan +5
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyFrontiersCrossref
  12. Weakly supervised computational pathology for prognostic stratification in locally advanced nasopharyngeal carcinoma: a multicenter external validation study
    Chao Jiang, Wenxuan Lu, Mingjun Ding +3
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyFrontiersCrossref
  13. Granzyme B as a predictive biomarker for therapeutic outcomes in non-small cell lung cancer patients undergoing anti-PD-1 therapy
    Kriti Jain, Asees Singh, Shyam Aggarwal +3
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyFrontiersCrossrefDOAJ
  14. Lymph node metastasis in head and neck squamous cell carcinoma: risk stratification, diagnosis, and management
    Jingmin You
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyFrontiersCrossref
  15. Postoperative radiotherapy versus systemic therapy alone for locally advanced esophageal squamous cell carcinoma following neoadjuvant chemoimmunotherapy
    Zongqian Yuan, Junfeng Zhao, Chunhui Li +5
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyFrontiersCrossref
  16. Case report: Definitive therapy for local progression in patients with responding metastatic HER2-positive breast cancer
    Yael Berner-Wygoda, Meredith Li, Mitchell Elliott +7
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyFrontiersCrossref
  17. Ultrastructural features associated with the dot-like cytokeratin pattern in Merkel cell carcinoma: a spectrum of intermediate filament organization
    Mateusz Krotofil, Maria Maksymowicz, Daria Owczarek +5
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyFrontiersCrossref
  18. ABCF2 is a prognostic and immunological pan-cancer biomarker with growth-promoting function in breast cancer: a multi-omics study
    Yinuan Shi, Yiyang Wang, Yongxiang Li +4
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyFrontiersCrossref
  19. Renal cell carcinoma organoids: establishment, applications, and clinical translation—current evidence, technical challenges, and future directions
    Haixiang Feng, Sizhe Wang, Junfeng Zhao
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyFrontiersCrossref
  20. Breast cancer metastasis to the thyroid gland: case report
    Xi Zhang, Hui Jin, Wenchao Qi +5
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyFrontiersCrossref
  21. CD66c-targeted CD40B adaptive transfer to enhance cytotoxic T cell responses in colorectal cancer
    Dhanapal Yogananthan, Ashok Raj Kattur Venkatachalam, Ramanathan Muthiah
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyFrontiersCrossref
  22. Salvage treatment incorporating arsenic trioxide for pediatric relapsed acute lymphoblastic leukemia: a retrospective real-world analysis
    Jia-Nan Li, Ji-Xun Lin, Cui-Yun Yang +12
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyFrontiersCrossref
  23. Reconstruction with a novel pedicled mucoperiosteal hinge flap and dura suturing: a new minimally invasive concept and closure technique for endoscopic endonasal surgery
    Zhengxing Xie, Chengyang Xie, Yan Zhuang +1
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyFrontiersCrossref
  24. Feature of esophageal cancer mortality in USA from 1999 to 2023: based on CDC WONDER database
    Mingfeng Wei, Shixiang Guo, Xiaoyu Chen +6
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyFrontiersCrossref
  25. HDAC1 inhibits CDX2 expression and promotes colorectal cancer cell migration
    Rina Mehmeti, José F. Carreño-Martinez, Nils Bodmer +4
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyFrontiersCrossref